PMI

What PMI does

PMI is a Mexican health and wellness company founded in 2022 and headquartered in Zapopan, Jalisco, that operates as an integrated developer, manufacturer, distributor, and marketer of health inputs, including herbal medicines, dietary supplements, and rapid diagnostic tests. The company's core activities span incubation, formulation, laboratory analysis, pilot and scaled batch production, clinical research protocols, regulatory dossier assembly, and commercialization of natural-origin pharmaceutical products designed to treat and diagnose disease with reduced side effects relative to synthetic alternatives. Its underlying technical stack combines ISO 9001:2015 quality systems with FDA-authorized raw material sourcing, and includes COFEPRIS-recognized pharmacovigilance and technovigilance units compliant with NOM-220-SSA1-2016, enabling drug and medical device safety monitoring within the Mexican regulatory framework.

The company operates a multi-country physical footprint consisting of manufacturing plants in Mexico, the United States, and Brazil, complemented by research laboratories in Israel, Spain, and the United Kingdom. Its product portfolio includes herbal medicines (Medicamentos Herbolarios), herbal remedies (Remedios Herbolarios), dietary supplements (Suplementos Alimenticios), a CBD/cannabis product line pending Mexican regulatory approval, and the STANDARD Q COVID-19 rapid test portfolio (antigen and IgM/IgG formats) commercialized through a strategic partnership with South Korea-based SD BIOSENSOR. Revenue is generated through direct B2B sales to enterprise healthcare providers, pharmaceutical companies, and commercial clients, complemented by contract development, manufacturing, and regulatory services for third parties. Go-to-market is sales-led, with distribution handled via direct enterprise sales and direct phone/email contact primarily in Mexico and Latin America.

Name

PMI

Legal name

PMI 12.10 S.A.P.I. de C.V.

Website

https://pmi1210.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

PMI is a Mexican health products company that develops, manufactures, and commercializes natural-origin herbal medicines, dietary supplements, and rapid COVID-19 diagnostics, serving enterprise healthcare providers, pharmaceutical companies, and commercial clients via contract development, manufacturing, and direct B2B sales.

Ownership category

akta.pro rank

Headquarters

HQ city

Zapopan

HQ country

Mexico

HQ region

Latin America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Products: Sale of herbal medicines, dietary supplements, and health products developed from natural-origin materials
2. Medical Devices - COVID Tests: Commercial sale of rapid COVID-19 tests from SD BIOSENSOR partnership for enterprise and commercial clients
3. Contract Development Services: Product development, formulation, clinical protocols, regulatory support, and manufacturing services for third-party pharmaceutical and health product companies
4. Regulatory Services: Dossier assembly, regulatory support, legal services, and inspections for warehouse, storage, and distribution operations

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

PMI is a Mexican pharmaceutical and health products company that incubates, develops, manufactures, and commercializes innovative natural-origin health products including herbal medicines, dietary supplements, and rapid COVID-19 diagnostic tests (STANDARD Q line via SD BIOSENSOR). It also offers end-to-end contract development and manufacturing services for third-party pharmaceutical and health product companies, from concept and formulation through clinical protocols, regulatory dossier, and finished certified product. The company additionally operates COFEPRIS-recognized pharmacovigilance and technovigilance units compliant with NOM-220-SSA1-2016 for drug and medical device safety monitoring.

Product overview

PMI is a Mexican health and wellness company focused on incubation, development, manufacturing, and commercialization of innovative products of natural origin. The portfolio includes COVID-19 rapid diagnostic tests through a partnership with SD BIOSENSOR (STANDARD Q product line: COVID-19 Ag Test, COVID-19 IgM/IgG Plus, and COVID-19 Ag Nasal), alongside a pipeline of herbal-based health products including dietary supplements, herbal remedies, herbal medicines, and CBD products. The company also provides pharmacovigilance and technovigilance services compliant with Mexican health regulations (NOM-220-SSA1-2016).

Differentiator

Problem solved

Functional benefit

Brands

• PMI BY SD BIOSENSOR: Product line featuring rapid COVID-19 tests from SD BIOSENSOR including STANDARD Q COVID-19 Ag Test, STANDARD Q COVID-19 IgM/IgG Plus, and STANDARD Q COVID-19 Ag Nasal

Products and services

• STANDARD Q COVID-19 Ag Test Rapid antigen test for COVID-19 detection providing results in 10-15 minutes using venous or capillary blood samples, distributed under PMI BY SD BIOSENSOR for enterprise and clinical customers.
• STANDARD Q COVID-19 IgM/IgG Plus Rapid antibody detection test for COVID-19 IgM and IgG antibodies distributed under PMI BY SD BIOSENSOR, intended for enterprise and clinical customers.
• STANDARD Q COVID-19 Ag Nasal Rapid nasal swab antigen test for COVID-19 designed for children, elderly, and sensitive individuals, delivering results in 15 minutes, distributed under PMI BY SD BIOSENSOR.
• Dietary Supplements (Suplementos Alimenticios) Herbal-based, plant-extract, traditional dehydrated or concentrated fruit products, optionally fortified with vitamins or minerals, presented in pharmaceutical form for dietary supplementation.
• Herbal Remedies (Remedios Herbolarios) Prepared medicinal plants or their parts presented in pharmaceutical form, attributed by popular or traditional knowledge for relief of symptoms; free-sale products with verified quality and safety.
• Herbal Medicines (Medicamentos Herbolarios) Products made with herbal material or derivatives whose therapeutic efficacy and safety have been scientifically confirmed in national or international literature.
• CBD Products (Productos de Cannabis) CBD (Cannabidiol) products manufactured by partner companies in the USA and FDA-approved, planned for commercialization in Mexico pending regulatory approval.
• Contract Development and Manufacturing Services End-to-end product development for pharmaceutical and health product companies covering requirement definition, laboratory analysis, pilot and cycled batches, clinical research protocols, validations, regulatory dossier, and finished certified product manufacturing using FDA-authorized raw materials.
• Regulatory and Legal Services Regulatory dossier assembly, regulatory submission support, legal services for products and projects, and inspections for warehouse, storage, and distribution operations, supporting COFEPRIS compliance.
• Pharmacovigilance Services Drug safety monitoring services delivered through a COFEPRIS-recognized pharmacovigilance unit operating under NOM-220-SSA1-2016, including adverse event identification, reporting, and evaluation.
• Technovigilance Services Medical device adverse event identification, reporting, and evaluation services delivered through a COFEPRIS-recognized technovigilance unit operating under NOM-220-SSA1-2016.

Quantifiable outcome

• COVID-19 test results available in 10-15 minutes depending on sample type

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• SD BIOSENSORcoreTechnology or IntegrationStrategic partnership with South Korean laboratory SD BIOSENSOR for distribution and commercialization of STANDARD Q COVID-19 rapid tests. The tests meet quality standards for application with high effectiveness for detection, available in three formats: venous blood and capillary blood (results in 10 minutes), nasopharyngeal (15 minutes), and nasal fossa for children, elderly, and sensitive individuals (15 minutes).
• Kana UndesacoreStrategic or Co-development PartnerStrategic alliance with Kana Undesa established to jointly offer rapid COVID-19 detection and monitoring tests from SD BIOSENSOR laboratory to the market. Combined efforts to provide enterprise COVID testing solutions.
• The Valens CompanyminorStrategic or Co-development PartnerCanadian cannabis company that announced two strategic agreements with PMI Mexico for product development and commercialization in the Mexican market.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• SD Biosensor: South Korean IVD manufacturer whose STANDARD Q rapid diagnostic tests are distributed in Mexico by PMI. Highly comparable because SD Biosensor defines the technical and commercial standards of the very IVD product line PMI sells, making it both partner and closest functional peer for the COVID-testing business.
• Laboratorios Sanfer: Mexican pharmaceutical manufacturer with own-brand generic and specialty products plus CDMO services. Comparable to PMI because both develop and manufacture pharmaceutical products domestically and compete for the same enterprise and institutional customers in Mexico.
• PiSA Farmacéutica: Mexican pharmaceutical company combining own-brand drug manufacturing with contract manufacturing and distribution services. Highly comparable to PMI due to overlapping business model of in-house pharma manufacturing, third-party development services, and regulatory expertise in the Mexican market.
• Genomma Lab Internacional: Mexico-based pharmaceutical and personal-care company with a portfolio of OTC and health products. Highly comparable to PMI because both target the Mexican consumer health market with branded products, operate their own manufacturing, and rely on regulatory expertise for market access.
• Laboratorios Liomont: Independent Mexican pharmaceutical manufacturer producing branded and generic drugs. Comparable to PMI as a Mexico-headquartered pharma manufacturer serving similar institutional and retail customers with domestically produced regulated products.

Broad incumbents

• Siegfried Holding: Swiss-headquartered CDMO offering API and finished-dose manufacturing services to pharma companies globally. Comparable to PMI's contract development and manufacturing capability, though Siegfried operates globally with established regulatory relationships that PMI is still building.
• Abbott: Global healthcare company with significant IVD and rapid diagnostic testing businesses, including COVID-19 rapid tests. Comparable to PMI's IVD distribution business as the dominant incumbent whose products and pricing set the competitive context for PMI's SD BIOSENSOR-distributed tests.
• Herbalife: Global nutrition and dietary supplements company with a multi-country manufacturing and distribution footprint. Comparable to PMI's dietary supplements and herbal product line, but Herbalife is a global incumbent operating direct-selling channels at far greater scale.
• Catalent: Global contract development and manufacturing organization (CDMO) serving pharma and biotech customers. Comparable to PMI's contract development and manufacturing service line, though Catalent operates at significantly larger scale across a broader therapeutic and geographic footprint.

Regional players

• Eurofarma: Brazilian pharmaceutical manufacturer with own brands and CDMO operations across Latin America. Comparable to PMI as a regional pharma manufacturer operating in PMI's manufacturing geography, but Eurofarma is a much larger incumbent focused primarily on the Brazilian market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/pmi-12-10-s-a-p-i-de-c-v

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PMI